Plandai Biotech Stock Probability of Future Pink Sheet Price Finishing Over 4.0E-4
| PLPL Stock | USD 0.0001 0.00 0.00% |
Plandai |
Plandai Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Plandai Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Plandai Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Plandai Biotech Technical Analysis
Plandai Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Plandai Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Plandai Biotech. In general, you should focus on analyzing Plandai Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Plandai Biotech Predictive Forecast Models
Plandai Biotech's time-series forecasting models is one of many Plandai Biotech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Plandai Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Plandai Biotech
Checking the ongoing alerts about Plandai Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Plandai Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Other Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.